Last Updated on January 15, 2019 by Sultan Beardsley
Leave a comment and click here to subscribe for MS article alerts and our newsletter!
January 2nd, Bristol-Myers Squibb announced a recent decision by the FDA to expand the indication for Sprycel (dasatinib). This decision expands the indication to patients one year or older with recently diagnosed “Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy.” Approval was granted after the phase 2 study CA180-372, promoting priority review by the FDA. This should boost prioritized brands up even further which are already up 83% since the 9-month period ending September 30th, 2017.
Further details on the phase two study and this expansion of indication by the FDA can be found by clicking here.
Who Is BMY?
Bristol-Myers Squibb is a New York based pharmaceutical company with annual revenues in excess of $20 billion annually. They have set out with the goal of “To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.” Currently the company trades at $52.43 and has been within a range of 46.94-70.05 within the last 52 weeks. Be sure to come back tomorrow for an in depth view of BMY and their positioning for penetration in the multiple melanoma market.
MS Money Moves and it’s Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.